Skip to content

Clinical Value Assessment of Electrosurgical Staplers in Laparoscopic Sleeve Gastrectomy and VATS Lobectomy

Clinical Value Assessment of Electrosurgical Staplers in Laparoscopic Sleeve Gastrectomy and VATS Lobectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108794
Enrollment
Unknown
Registered
2025-09-05
Start date
2025-06-03
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Electric stapler :Electric stapler
Manual stapler:Manual stapler

Sponsors

Huashan Hospital, Fudan University, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: For laparoscopic sleeve gastrectomy: 1. Age 18-70 years old, gender not restricted; 2. Meet the surgical indications as stipulated in the "Chinese Guidelines for Surgical Treatment of Obesity and Metabolic Diseases (2024 Edition)" [9] and have been admitted to our hospital to plan for laparoscopic sleeve gastrectomy; 3. Complete clinical data of the patient. For VATS lobectomy: 1. Age 18-70 years old, gender not restricted; 2. Meet the surgical indications for lobectomy and the results of pulmonary function tests show that the patient can tolerate lobectomy; have been admitted to our hospital to plan for VATS lobectomy, as follows: 1) Non-small cell lung cancer in stage I/II and some stage III; 2) Other malignant tumors requiring lobectomy; 3) Benign lesions where lesion resection or pulmonary wedge resection is difficult due to the lesion being close to the hilum, involving a large part or the entire lung lobe. 3. Complete clinical data of the patient.

Exclusion criteria

Exclusion criteria: Regarding laparoscopic sleeve gastrectomy: 1. It has one of the surgical contraindications listed in the "Chinese Guidelines for Surgical Treatment of Obesity and Metabolic Diseases (2024 Edition)": a. A clear diagnosis of non-obese type 1 diabetes; b. Pregnant women with diabetes and certain special types of diabetes; c. Patients who abuse drugs, are addicted to alcohol or have mental and psychological disorders that are not well controlled; d. Those with intellectual disabilities or immature intelligence, and whose behavior cannot be self-controlled; e. Those whose expectations for surgical weight loss do not match the actual situation; f. Those unwilling to bear the potential risks of surgical complications; g. Those who cannot cooperate with the changes in diet and lifestyle after surgery and have poor compliance; h. Those with poor overall condition and are unable to tolerate general anesthesia or surgery. 2. Has used hypoglycemic drugs or statin lipid-lowering drugs before or currently; 3. Has undergone gastric or intestinal surgery before; 4. Has suffered from liver and gallbladder diseases other than alcoholic fatty liver disease before or currently; 5. Has suffered from chronic organic intestinal diseases before or currently; 6. Has a history of excessive alcohol consumption: for men, the equivalent ethanol intake over the past 12 months is greater than 30g/d, and for women, it is greater than 20g/d; 7. Had acute gastroenteritis within one month before the surgery; 8. Used antibiotics or acid-suppressing drugs within one month before the surgery; 9. Has mental or neurological disorders, and cannot express one's will correctly; 10. Has other serious diseases that affect the evaluation of this study and cannot cooperate; 11. Cannot understand the procedures and methods of this clinical study, refuses to participate and refuses to sign the informed consent form. For thoracoscopic lobectomy: 1. Central lung cancer with mediastinal lymph node metastasis and invasion or extensive spread; 2. Severe dense adhesions in the thoracic cavity, including severe inflammatory lesions and pleural fusion; 3. Stage IIIB - IIIB NSCLC with cancer tissue invading the main bronchus or the main pulmonary artery; 4. The results of pulmonary function tests are intolerable for lobectomy; 5. Unable to tolerate one-lung ventilation; 6. Large tumors (diameter > 6 cm); 7. Mental or neurological disorders, unable to express wishes correctly; 8. Other serious diseases that affect the evaluation of this study cannot be controlled; 9. Unable to understand the procedures and methods of this clinical study and refuse to participate and refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Event-free survival rate ;

Secondary

MeasureTime frame
The inoperative performance of medical staplers;Operational convenience;The incidence of postoperative anastomotic fistula/ stump fistula complications;Duration of the surgery;Postoperative hospital stay duration;Post-operative fatigue of medical staff;

Countries

China

Contacts

Public ContactLei Zhang,Liewen Pang,Rong Hua

Huashan Hospital, Fudan University, China

ZL_FIRE99@Sina.com+86 138 1691 8236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026